Action HOOK HOOKIPA PHARMA INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués HOOKIPA Pharma Inc.

Actions

HOOK

US43906K1007

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/06/2024 		Varia. 5j. Varia. 1 janv.
0,64 USD 0,00% Graphique intraday de HOOKIPA Pharma Inc. -9,37% -20,99%
05/06 HOOKIPA PHARMA INC. : Opinion positive de HC Wainwright ZM
04/06 Transcript : HOOKIPA Pharma Inc. - Special Call

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna
AQ
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
GL
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
GL
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
GL
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
GL
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
GL
HOOKIPA Pharma Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GL
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
GL
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
AQ
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
GL
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
GL
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
GL
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
AQ
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
AQ
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
AQ
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
GL
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
GL
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action HOOK
  4. Actualités HOOKIPA Pharma Inc.
  5. Communiqués